Litcius/Paper detail

An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)

Rita Trozzi, Sandra Tuyaerts, Daniela Annibali, Alejandro Herreros‐Pomares, Lotte Boog, Peter A. van Dam, Karin Leunen, Christophe M. Deroose, Hans Trum, Frédéric Amant

2024International Journal of Gynecological Cancer10 citationsDOI

Topics & Concepts

MedicineFulvestrantOpen labelOncologyEstrogen receptorEstrogenInternal medicinePhases of clinical researchSingle CenterStage (stratigraphy)GynecologyToxicityClinical trialCancerBreast cancerPaleontologyBiologyEndometrial and Cervical Cancer TreatmentsEstrogen and related hormone effectsUterine Myomas and Treatments
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study) | Litcius